A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB) Implantation in Rescue Interbody Fusion

Trial Profile

A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB) Implantation in Rescue Interbody Fusion

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ALLOB-RIF1
  • Sponsors Bone Therapeutics
  • Most Recent Events

    • 29 Nov 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
    • 29 Nov 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2019.
    • 29 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top